Electronic Biosciences, Inc.

Electronic Biosciences, Inc., a San Diego-based biotechnology firm, develops nanopore-based sequencing and diagnostic platforms for life sciences research and clinical applications, operating exclusively as a prime recipient of federal grants under NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, with a recent $2.999975 million NIH definitive contract award for a unified nanopore platform enabling simultaneous DNA, RNA, and protein sequencing (September 2026).

The company competes under total small business set-asides across its federal footprint. Electronic Biosciences specializes in single-molecule protein sequencing via nanopore technology, RNA modification detection and sequencing (pseudouridine, m6A, methylcytosine, inosine), point-of-care diagnostic assays (prostate-specific antigen, immunosuppressant drug monitoring, type 1 diabetes autoantibody detection), extracellular vesicle characterization, and advanced oncological DNA sequencing for microsatellite instability detection. Representative grant work includes a $418,854 National Cancer Institute Cancer Biology Research grant (CFDA 93.396) for next-generation oncoproteomic protein sequencing through June 2028; a $389,535 National Cancer Institute SBIR Phase I award for at-home PSA testing (completion September 2025); a National Human Genome Research Institute SBIR grant for RNA sequencing technology ("SpinSeq") enabling high-precision RNA modification detection through May 2027; and a National Institute of General Medical Sciences Phase I STTR collaboration with University of Utah faculty for comprehensive extracellular vesicle characterization at the single-vesicle level.

Customer concentration centers on the National Institutes of Health ecosystem. The top five funding agencies account for 68% of recent award volume, led by the National Human Genome Research Institute (17 awards) and NIH broadly (12 awards, $3 million combined potential value). By dollar magnitude, the Department of Homeland Security Science and Technology Directorate anchors the portfolio with a single $4.5 million award, followed by NIH ($3 million across 12 awards), the Defense Advanced Research Projects Agency ($2.4 million across 3 awards), and the Army Medical Command ($1.1 million across 3 awards). Electronic Biosciences has worked with 17 distinct federal agencies across a 72-award footprint spanning two decades, with NIH-aligned work—particularly SBIR and STTR mechanisms—representing the dominant vehicle for funding development-stage sequencing and diagnostic technologies.

Award activity has trended modestly upward in prior years (5 awards in 2022 to 8 awards in 2023) before declining to 4 awards annually in 2024 and 2025, with 2 awards recorded through September 2026. Six awards carrying combined potential value of $3 million face ultimate completion within the next twenty-four months, presenting recompete exposure. The source data show 72 total awards with combined potential value of $12.5 million, though obligated dollars total $59.8 million across the footprint, indicating substantial completion of development work and transition toward commercialization or operational deployment of validated platforms.